Excess belly fat may hamper effectiveness of IBD meds: study
Patients with more abdominal visceral fat are less likely to achieve remission or improvement, say US doctors.
Patients with higher levels of intra-abdominal visceral fat are less likely to achieve improvements from biologic treatments for inflammatory bowel disease, a US study shows.
Those with higher visceral adiposity also had lower levels of the biologic medications in their bloodstream than those with lower abdominal fat, according to doctors from Cedars-Sinai Medical Center in Los Angeles.
